We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is working to develop and finalize a handful of new guidances on bringing complex generics to market — including complicated medicines that may require alternate methods of establishing bioequivalence, as well as drug-device combination products that may be blocked by iterative patents. Read More
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval for a single generic medicine and expansions of indications for six other drugs, during a light meeting this past month. Read More